Study: NCT03679143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 100 mg
Description: ZSP1273 tablet administered orally once daily under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 100 mg
Description: Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 200 mg
Description: ZSP1273 tablets administered orally once daily under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 200 mg
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 400 mg
Description: ZSP1273 tablets administered orally once daily in the fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 400 mg
Description: Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 600 mg
Description: ZSP1273 tablets administered orally once daily under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 600 mg
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 900 mg
Description: ZSP1273 tablets administered orally once daily in the fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 900 mg
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 1200 mg
Description: ZSP1273 tablets administered orally once daily in the fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1200 mg
Description: Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: ZSP1273 tablets administered orally once daily under fasted or fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 Low Dose
Description: ZSP1273 tablets administered orally once daily under fasted or fed condition for 5 Days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 Median Dose
Description: ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 High Dose
Description: ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.